Literature DB >> 17197121

Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy.

Alfons C M van den Bergh1, Gerrit van den Berg, Michiel A Schoorl, Wim J Sluiter, Anton M van der Vliet, Eelco W Hoving, Ben G Szabó, Johannes A Langendijk, Bruce H R Wolffenbuttel, Robin P F Dullaart.   

Abstract

PURPOSE: To demonstrate the benefit of immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma (NFA) in perspective to the need for hormonal substitution and life expectancy. METHODS AND MATERIALS: Retrospective cohort analysis of 122 patients, operated for NFA between 1979 and 1998. Recurrence was defined as regrowth on computed tomography or magnetic resonance imaging. The occurrence of hormonal deficiencies was defined as the starting date of hormonal substitution therapy.
RESULTS: Seventy-six patients had residual NFA after surgery and received immediate postoperative radiotherapy (Group 1); three patients developed a recurrence, resulting in a 95% local control rate at 10 years. Twenty-eight patients had residual NFA after surgery, but were followed by a wait-and-see policy (Group 2). Sixteen developed a recurrence, resulting in a local control rate of 49% at 5 years and 22% at 10 years (p < 0.001 compared with Group 1). There were no differences between Group 1 and 2 regarding the need for substitution with thyroid hormone, glucocorticoids, and sex hormones before first surgery, directly after surgery and at end of follow-up. There were no differences in hormone substitution free survival between Group 1 and Group 2 during the study period after first surgery. Life expectancy was similar in Group 1 and 2, and their median life expectancy did not differ from median life expectancy in the general population.
CONCLUSIONS: Immediate postoperative radiotherapy provides a marked improvement of local control among patients with residual NFA compared with surgery alone, without an additional deleterious effect on pituitary function and life expectancy.

Entities:  

Mesh:

Year:  2006        PMID: 17197121     DOI: 10.1016/j.ijrobp.2006.09.049

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  Safety and efficacy of multisession gamma knife radiosurgery for residual or recurrent pituitary adenomas.

Authors:  Luigi Albano; Marco Losa; Francesco Nadin; Lina Raffaella Barzaghi; Veronica Parisi; Antonella Del Vecchio; Angelo Bolognesi; Pietro Mortini
Journal:  Endocrine       Date:  2019-02-23       Impact factor: 3.633

Review 2.  The role of radiation therapy in the management of non-functioning pituitary adenomas.

Authors:  M Losa; P Picozzi; M Motta; M Valle; A Franzin; P Mortini
Journal:  J Endocrinol Invest       Date:  2011-03-22       Impact factor: 4.256

Review 3.  The postoperative monitoring of nonfunctioning pituitary adenomas.

Authors:  John A H Wass; Raghava Reddy; Niki Karavitaki
Journal:  Nat Rev Endocrinol       Date:  2011-04-05       Impact factor: 43.330

Review 4.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery.

Authors:  Neil Forster; Ronald Warnick; Vinita Takiar; Luke Pater; John Breneman
Journal:  J Neurooncol       Date:  2018-02-15       Impact factor: 4.130

6.  Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Authors:  I Jonathan Pomeraniec; Hideyuki Kano; Zhiyuan Xu; Brandon Nguyen; Zaid A Siddiqui; Danilo Silva; Mayur Sharma; Hesham Radwan; Jonathan A Cohen; Robert F Dallapiazza; Christian Iorio-Morin; Amparo Wolf; John A Jane; Inga S Grills; David Mathieu; Douglas Kondziolka; Cheng-Chia Lee; Chih-Chun Wu; Christopher P Cifarelli; Tomas Chytka; Gene H Barnett; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurosurg       Date:  2017-10-27       Impact factor: 5.115

7.  Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.

Authors:  Valentina Gasco; Marina Caputo; Valeria Cambria; Guglielmo Beccuti; Mirko Parasiliti Caprino; Ezio Ghigo; Mauro Maccario; Silvia Grottoli
Journal:  Endocrine       Date:  2018-10-19       Impact factor: 3.633

Review 8.  STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?

Authors:  M L Gheorghiu; M Fleseriu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

9.  Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas.

Authors:  Won Kim; Claire Clelland; Isaac Yang; Nader Pouratian
Journal:  Surg Neurol Int       Date:  2012-04-26

10.  Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy.

Authors:  Rohan R Lall; Stephen F Shafizadeh; Kyung-Hwa Lee; Qinwen Mao; Minesh Mehta; Jeffrey Raizer; Bernard R Bendok; James P Chandler
Journal:  Surg Neurol Int       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.